At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Oxaliplatindrug
Likely dose
Oxaliplatin 130 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Oxaliplatin for Non-Hodgkin's Lymphoma. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP). Clinical efficacy and toxicity of this ESHAOX salvage regimen will be evaluated in refractory or relapsed non-Hodgkin's lymphoma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesSouth Korea
CollaboratorsBoryung Pharmaceutical Co., Ltd
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionDec 2006
Study CompletionJan 2008
TodayJul 2026
First PostedJun 14, 2006
Enrollment StartJun 1, 2006
Primary CompletionDec 1, 2006
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.1 years ago
Interventions
Oxaliplatindrug
Oxaliplatin, 130 mg per square meter, on day 1